About this trial
Hypothesis 1a: The investigators anticipate that navigator decision coaching, compared to enhanced usual care (EUC) will result in higher quality SDM for lung cancer screening (LCS )(primary outcome), greater knowledge of lung cancer screening benefits and harms, and lower decisional conflict.
Hypothesis 1b: Compared to enhanced usual care (EUC), we expect that TELESCOPE will result in more screening discussions, increased initial for lung cancer screening (LCS) with low-dose CT scan (LDCT) uptake among interested participants, increased adherence to repeat LCS and diagnostic testing, and increased smoking cessation referrals for current smokers.
Hypothesis 2: The investigators expect that a "booster" coaching session will increase adherence to repeat lung cancer screening (LCS).
Eligibility criteria
Qualifiers
Be 50 to 77 years of age
Be a current or former smoker having quit within the past 15 years
Have at least a 20 pack-year smoking history
Be scheduled for a non-acute care visit at one of the study sites. Interviews (N=50)
Disqualifiers
Do not speak English
Have a history lung cancer
Were screened for lung cancer within the past 12 months
Have health conditions that make them poor candidates for curative treatment as determined by the primary care provider
Trial design
Treatments tested in this trial
- TELESCOPE, Remote Decision Coaching with Navigation Intervention
Treatment groups
Locations
2Sponsors and collaborators
Rutgers, The State University of New Jersey
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator